The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of 
Advanced EGFR Mutant Non-small Cell Lung Cancer Patients

Background and objective Targeted therapy in non-small cell lung cancer (NSCLC) had become a research hotspot. Both of gefitinib and erlotinib had already been recommended as first line treatment in epidermal growth factor receptor (EGFR) mutant advanced NSCLC patients. The study aimed to compare th...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Yuxiang MA, Yan HUANG, Hongyun ZHAO, Junling LIU, Likun CHEN, Haiying WU, Ningning ZHOU
Fformat:	Artigo
Iaith:	Chinês
Cyhoeddwyd:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2013-04-01
Cyfres:	Chinese Journal of Lung Cancer
Pynciau:	Gefitinib Erlotinib Lung neoplasms Cost-effectiveness analysis
Mynediad Ar-lein:	http://dx.doi.org/10.3779/j.issn.1009-3419.2013.04.06
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!